Evusheld positive CHMP opinion in EU
16 September 2022 07:05 BST Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19 Recommendation based on TACKLE Phase III treatment data showing reduced risk of severe COVID-19 or death AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are